Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431339 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 739
- Enrollment target
NCT01431339 is a Phase 3 study that has completed, run by Durata Therapeutics Inc., an affiliate of Allergan. The registered enrollment target is 739 participants.
The verdict
NCT01431339, a Phase 3 study, has completed, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 739 participants
- Enrollment target
Study Summary
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.
Interventions
- DRUG IV Dalbavancin
- DRUG Vancomycin/Linezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 739 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431339
The ClinicalTrials.gov registry entry for NCT01431339 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV Dalbavancin is the first listed.
NCT01431339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01431339 about?
NCT01431339 is a clinical study titled "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infect...
What is the current status of trial NCT01431339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 739 participants. The study started on 2011-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01431339?
The interventions under investigation include: IV Dalbavancin (DRUG), Vancomycin/Linezolid (DRUG).
Who is sponsoring clinical trial NCT01431339?
This trial is sponsored by Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.